WO2001076600A2 - Inhibition of cytokine generation - Google Patents

Inhibition of cytokine generation Download PDF

Info

Publication number
WO2001076600A2
WO2001076600A2 PCT/US2001/011474 US0111474W WO0176600A2 WO 2001076600 A2 WO2001076600 A2 WO 2001076600A2 US 0111474 W US0111474 W US 0111474W WO 0176600 A2 WO0176600 A2 WO 0176600A2
Authority
WO
WIPO (PCT)
Prior art keywords
desloratadine
allergic
basophils
inhibition
generation
Prior art date
Application number
PCT/US2001/011474
Other languages
English (en)
French (fr)
Other versions
WO2001076600A3 (en
Inventor
Robert P. Schleimer
John Schroeder
William Kreutner
Original Assignee
Schering Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corporation filed Critical Schering Corporation
Priority to EP01928407A priority Critical patent/EP1267870A2/en
Priority to CA002405413A priority patent/CA2405413A1/en
Priority to MXPA02009821A priority patent/MXPA02009821A/es
Priority to JP2001574117A priority patent/JP2003530351A/ja
Priority to AU2001255268A priority patent/AU2001255268A1/en
Publication of WO2001076600A2 publication Critical patent/WO2001076600A2/en
Publication of WO2001076600A3 publication Critical patent/WO2001076600A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PCT/US2001/011474 2000-04-07 2001-04-05 Inhibition of cytokine generation WO2001076600A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP01928407A EP1267870A2 (en) 2000-04-07 2001-04-05 Inhibition of cytokine generation
CA002405413A CA2405413A1 (en) 2000-04-07 2001-04-05 Inhibition of cytokine generation
MXPA02009821A MXPA02009821A (es) 2000-04-07 2001-04-05 Inhibicion de la generacion de citocina.
JP2001574117A JP2003530351A (ja) 2000-04-07 2001-04-05 サイトカイン生成の阻害
AU2001255268A AU2001255268A1 (en) 2000-04-07 2001-04-05 Inhibition of cytokine generation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19601600P 2000-04-07 2000-04-07
US60/196,016 2000-04-07

Publications (2)

Publication Number Publication Date
WO2001076600A2 true WO2001076600A2 (en) 2001-10-18
WO2001076600A3 WO2001076600A3 (en) 2002-06-27

Family

ID=22723784

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/011474 WO2001076600A2 (en) 2000-04-07 2001-04-05 Inhibition of cytokine generation

Country Status (6)

Country Link
EP (1) EP1267870A2 (es)
JP (1) JP2003530351A (es)
AU (1) AU2001255268A1 (es)
CA (1) CA2405413A1 (es)
MX (1) MXPA02009821A (es)
WO (1) WO2001076600A2 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1670427A2 (en) * 2003-09-15 2006-06-21 CombinatoRx, Incorporated Methods and reagents for the treatment of immunoinflammatory disorders

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595997A (en) * 1994-12-30 1997-01-21 Sepracor Inc. Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595997A (en) * 1994-12-30 1997-01-21 Sepracor Inc. Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HAYASHI S. ET AL: "Anti-inflammatory actions of new antihistamines." CLINICAL AND EXPERIMENTAL ALLERGY, (1999) 29/12 (1593-1596). , XP001025988 *
LIPOZENCIC J.: "The EAACI 1997 annual meeting - A message from he meeting Rhodes, June 1-5, 1997." ACTA DERMATOVENEROLOGICA CROATICA, (1997) 5/2 (69-80). , XP001018736 *
LIPPERT, U. ET AL: "Pharmacological modulation of IL-6 and IL-8 secretion by the H1-antagonist decarboethoxy-loratadine and dexamethasone by human mast and basophilic cell lines" EXP. DERMATOL. (1995), 4(4, PT. 2), 272-6 , XP001001161 *
SEGURA T. ET AL: "Allergic rhinitis: Basic pathophysiology and therapeutic strategies." CANADIAN JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, (1999) 4/7 (318-330). , XP000998728 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1670427A2 (en) * 2003-09-15 2006-06-21 CombinatoRx, Incorporated Methods and reagents for the treatment of immunoinflammatory disorders
EP1670427A4 (en) * 2003-09-15 2009-01-07 Combinatorx Inc METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNO-INFLAMMATORY DISORDERS

Also Published As

Publication number Publication date
MXPA02009821A (es) 2003-03-27
EP1267870A2 (en) 2003-01-02
AU2001255268A1 (en) 2001-10-23
CA2405413A1 (en) 2001-10-18
WO2001076600A3 (en) 2002-06-27
JP2003530351A (ja) 2003-10-14

Similar Documents

Publication Publication Date Title
Du Buske Clinical comparison of histamine H1–receptor antagonist drugs
Grant et al. Cetirizine in patients with seasonal rhinitis and concomitant asthma: prospective, randomized, placebo-controlled trial
US20030229030A1 (en) Method of treating interleukin-6-mediated inflammatory diseases
Hurst et al. Ebastine: an update of its use in allergic disorders
Murdoch et al. Desloratadine: an update of its efficacy in the management of allergic disorders
Keam et al. Rupatadine: a review of its use in the management of allergic disorders
US20060276495A1 (en) Treatment methods of nasal congestion and nasal obstruction
US20080262018A1 (en) Treating allergic and inflammatory conditions
Terrien et al. Comparison of the effects of terfenadine with fexofenadine on nasal provocation tests with allergen
Rendi-Wagner et al. Unexpected frequency, duration and spectrum of adverse events after therapeutic dose of mefloquine in healthy adults
US6599914B2 (en) Inhibition of cytokine generation
Archana et al. Antipyretic and analgesic activities of Caesalpinia bonducella seed kernel extract
CN107635564B (zh) 人参皂苷m1用于预防或治疗硅肺病的用途
TW202333726A (zh) 以ｓｓａｏ抑制劑治療肝病
Day Pros and cons of the use of antihistamines in managing allergic rhinitis
EP1272191A2 (en) An efficacious dosage regimen of galantamine that reduces side effects
EP1267870A2 (en) Inhibition of cytokine generation
WO2008058033A2 (en) Soluble epoxide hydrolase inhibitors for the treatment of rheumatoid arthritis
Lordan et al. H1-antihistamines in asthma
Borade et al. Modern H1-antihistamines in asthma
Vivero et al. A close look at fenfluramine and dexfenfluramine
Lotrich et al. Dextromethorphan-induced delirium and possible methadone interaction
Ibrahim et al. Study of the correlation between clozapine levels and clinical findings in acutely intoxicated patients admitted to poison control Center-Ain Shams University hospitals: 6 months (a prospective study)
Sorensen et al. Low-level resistance to camptothecin in a human small-cell lung cancer cell line without reduction in DNA topoisomerase I or drug-induced cleavable complex formation
Davis et al. Muscarinic Receptor Antagonism and Allergen Induced Airway Responses in Allergic Asthma: A Scoping Review

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CZ DE DK DM DZ EE ES FI GB GD GE HR HU ID IL IN IS JP KG KR KZ LC LK LR LT LU LV MA MD MG MK MN MX MZ NO NZ PL PT RO RU SE SG SI SK SL TJ TM TR TT TZ UA US UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CZ DE DK DM DZ EE ES FI GB GD GE HR HU ID IL IN IS JP KG KR KZ LC LK LR LT LU LV MA MD MG MK MN MX MZ NO NZ PL PT RO RU SE SG SI SK SL TJ TM TR TT TZ UA US UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2405413

Country of ref document: CA

ENP Entry into the national phase in:

Ref country code: JP

Ref document number: 2001 574117

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/009821

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2001928407

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001928407

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001928407

Country of ref document: EP